ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses
On August 13, ADC Therapeutics (NYSE:ADCT) held its second-quarter earnings call and delivered a mixed message that investors are still sorting through.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 0 | $0 | 0% | ||
| 2. | 0 | $0 | 0% | ||
| 3. | Alyeska Investment Group Anand Parekh | 0 | $0 | 0% | |
| 4. | Renaissance Technologies Jim Simons | 0 | $0 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.75 | 10,000 | $27,500.00 | 20,000 | 2009-03-06 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 33,187 | $10,538 | 0.04% | |
| 2. | 1 | $13 | 0% |